167 related articles for article (PubMed ID: 33121412)
21. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2.
Cheon SY; Koo BN
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360684
[TBL] [Abstract][Full Text] [Related]
23. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
24. Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
Kabeerdoss J; Danda D
Int J Rheum Dis; 2020 Aug; 23(8):998-1008. PubMed ID: 32779341
[TBL] [Abstract][Full Text] [Related]
25. Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?
Giovinazzo G; Gerardi C; Uberti-Foppa C; Lopalco L
Molecules; 2020 Dec; 25(24):. PubMed ID: 33322757
[TBL] [Abstract][Full Text] [Related]
26. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
Misra DP; Agarwal V; Gasparyan AY; Zimba O
Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
[TBL] [Abstract][Full Text] [Related]
27. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".
Giuliani C; Bucci I; Napolitano G
Med Hypotheses; 2021 Jan; 146():110473. PubMed ID: 33385879
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive review on sarilumab in COVID-19.
Khiali S; Rezagholizadeh A; Entezari-Maleki T
Expert Opin Biol Ther; 2021 May; 21(5):615-626. PubMed ID: 33161757
[No Abstract] [Full Text] [Related]
29. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
30. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
31. Complement cascade in severe forms of COVID-19: Recent advances in therapy.
Chouaki Benmansour N; Carvelli J; Vivier E
Eur J Immunol; 2021 Jul; 51(7):1652-1659. PubMed ID: 33738806
[TBL] [Abstract][Full Text] [Related]
32. The cytokine storm and COVID-19.
Hu B; Huang S; Yin L
J Med Virol; 2021 Jan; 93(1):250-256. PubMed ID: 32592501
[TBL] [Abstract][Full Text] [Related]
33. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
[TBL] [Abstract][Full Text] [Related]
34. The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S; Shariati L; Boshtam M; Rahimmanesh I; Mirian M; Esmaeili Y; Najaflu M; Khanahmad N; Zeinalian M; Trovato M; Tay FR; Khanahmad H; Makvandi P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34064039
[TBL] [Abstract][Full Text] [Related]
35. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis guided therapeutic management of COVID-19: an immunological perspective.
Kumar A; Prasoon P; Sekhawat PS; Pareek V; Faiq MA; Kumari C; Narayan RK; Kulandhasamy M; Kant K
Int Rev Immunol; 2021; 40(1-2):54-71. PubMed ID: 33111578
[TBL] [Abstract][Full Text] [Related]
37. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
[TBL] [Abstract][Full Text] [Related]
38. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
Dzobo K; Chiririwa H; Dandara C; Dzobo W
OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
[TBL] [Abstract][Full Text] [Related]
39. Oxytocin as a Potential Adjuvant Against COVID-19 Infection.
Thakur P; Shrivastava R; Shrivastava VK
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1155-1162. PubMed ID: 32914732
[TBL] [Abstract][Full Text] [Related]
40. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
